Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) disorders and diseases. The company is advancing vonoprazan, a clinical candidate and a new potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs for patients with gastroesophageal reflux disease (GERD) and other acid-related conditions. Phathom has assembled a leadership team of experienced GI and pharmaceutical industry experts with a successful track record in developing and commercializing highly innovative therapies.